Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Incyte Corp
(NQ:
INCY
)
76.13
+2.01 (+2.71%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Nov 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,261,651
Open
74.12
Bid (Size)
74.72 (2)
Ask (Size)
77.26 (1)
Prev. Close
74.12
Today's Range
73.91 - 76.33
52wk Range
50.35 - 76.33
Shares Outstanding
222,430,635
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Stock Market Retreats Before Election Day; Microsoft, Apple, Amazon, Google, Meta In Focus: Weekly Review
November 01, 2024
The major indexes declined, but haven't fallen apart.
Via
Investor's Business Daily
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
October 30, 2024
Incyte reports strong Q3 earnings, driven by Jakafi growth, prompting BofA upgrade with a new price target of $90.
Via
Benzinga
Performance
YTD
+16.32%
+16.32%
1 Month
+13.56%
+13.56%
3 Month
+22.79%
+22.79%
6 Month
+40.77%
+40.77%
1 Year
+38.80%
+38.80%
More News
Read More
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
October 30, 2024
Via
Benzinga
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
October 29, 2024
Via
Investor's Business Daily
Peeling Back The Layers: Exploring Incyte Through Analyst Insights
October 23, 2024
Via
Benzinga
This Alphabet Analyst Turns Bullish; Here Are Top 5 Downgrades For Wednesday
October 30, 2024
Via
Benzinga
Incyte to Present at Upcoming Investor Conferences
October 30, 2024
From
Incyte
Via
Business Wire
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
October 29, 2024
Via
Benzinga
Corning Posts Upbeat Q3 Earnings, Joins Opera, Inari Medical, Incyte And Other Big Stocks Moving Higher On Tuesday
October 29, 2024
Via
Benzinga
Uncovering Noteworthy Technical Analysis Findings for INCYTE CORP (NASDAQ:INCY).
October 14, 2024
Via
Chartmill
A Look Into Incyte Inc's Price Over Earnings
October 10, 2024
Via
Benzinga
Assessing Incyte: Insights From 11 Financial Analysts
October 01, 2024
Via
Benzinga
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
October 29, 2024
From
Incyte
Via
Business Wire
Incyte Named One of Top 5 Companies on Science Magazine’s 2024 Top Employers List
October 24, 2024
From
Incyte
Via
Business Wire
Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program
October 10, 2024
From
Incyte
Via
Business Wire
Incyte to Report Third Quarter Financial Results
October 08, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 07, 2024
From
Incyte
Via
Business Wire
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 03, 2024
From
Incyte
Via
Business Wire
Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate
September 30, 2024
Via
Benzinga
Exposures
Product Safety
Multiple Late-Breaking Data Presentations from Incyte’s Dermatology Portfolio will be Featured at the European Academy of Dermatology and Venereology (EADV) 2024 Congress
September 25, 2024
From
Incyte
Via
Business Wire
Incyte Downgraded - Analyst Notes Intense Competition, Particularly In Larger Markets
September 18, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Wall Street Lower Ahead Of Interest Rate Move
September 18, 2024
Via
Talk Markets
Intel Leads S&P 500 Monday, And Keeps Running Late; Apple Chipmakers Are Biggest Losers
September 16, 2024
Via
Investor's Business Daily
Topics
Stocks
Exposures
US Equities
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of Clinical Activity in Patients with Advanced Solid Tumors, Notably Ovarian Cancer
September 14, 2024
From
Incyte
Via
Business Wire
Incyte’s Retifanlimab (Zynyz®) Extends Progression-Free Survival in Patients with Squamous Cell Anal Carcinoma (SCAC); Data Featured at ESMO 2024 Presidential Symposium
September 14, 2024
From
Incyte
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.